half-life is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Specific gravity—(using a hydrometer test strip or some sort of floating indicator), Refractometer—which measures the refractive index of the antifreeze solution, and Test strips—specialized, disposable indicators made for this purpose. Both specific gravity and refractive index are affected by temperature, although the former is affected much less catastrophically. Temperature compensation is nevertheless recommended for RI measurement. Propylene glycol solutions cannot be tested using specific gravity because of ambiguous results (40% and 100% solutions have the same specific gravity), although typical uses rarely exceed 60% concentration. The boiling point can be similarly determined by a concentration given from one of the three methods. Datasheets for glycol/water coolant mixtures are commonly available from chemical vendors.
=== Capped score === In addition, the fact that four proteins, all with different amino acid profiles, receive identical scores of 1.0 limits its usefulness as a comparative tool. Since they have different compositions, it is natural to assume that they perform differently in the human body and should have different scores. In short, this method, however, gives no distinction of their performance relative to each other, because after they pass a certain point, they are all capped at 1.0 and receive an identical rating. This is because in 1990 at a FAO/WHO meeting, it was decided that proteins having values higher than 1.0 would be rounded or "leveled down" to 1.0 as scores above 1.0 are considered to indicate the protein contains essential amino acids in excess of the human requirements. An uncapped version can still be computed by multiplying PD with AAS.
== Example of preparing a series of standard solutions == Suppose the concentration of glutamine in an unknown sample needs to be measured. To do so, a series of standard solutions containing glutamine is prepared to create a calibration curve. A table summarizing a method for creating these solutions is shown below:
The Royal Proclamation of 1763 established First Nation treaty rights, created the Province of Quebec out of New France, and annexed Cape Breton Island to Nova Scotia. St John's Island (now Prince Edward Island) became a separate colony in 1769. To avert conflict in Quebec, the British Parliament passed the Quebec Act 1774, expanding Quebec's territory to the Great Lakes and Ohio Valley. More importantly, the Quebec Act afforded Quebec special autonomy and rights of self-administration at a time when the Thirteen Colonies were increasingly agitating against British rule. It re-established the French language, Catholic faith, and French civil law there, staving off the growth of an independence movement in contrast to the Thirteen Colonies. The Proclamation and the Quebec Act in turn angered many residents of the Thirteen Colonies, further fuelling anti-British sentiment in the years prior to the American Revolution. After the American War of Independence, the 1783 Treaty of Paris recognized the independence of the United States and set the terms of peace, ceding British North American territories south of the Great Lakes and east of the Mississippi River to the new country. The American war of independence also caused a large out-migration of Loyalists, the settlers who had fought against American independence. Many moved to Canada, particularly Atlantic Canada, where their arrival changed the demographic distribution of the existing territories.
Sources: en.wikipedia.org
== Exchange reaction == In protic solution exchangeable protons such as those in hydroxyl or amine group exchange protons with the solvent. If D2O is solvent, deuterons will be incorporated at these positions. The exchange reaction can be followed using a variety of methods (see Detection). Since this exchange is an equilibrium reaction, the molar amount of deuterium should be high compared to the exchangeable protons of the substrate. For instance, deuterium is added to a protein in H2O by diluting the H2O solution with D2O (e.g. tenfold). Usually exchange is performed at physiological pH (7.0–8.0) where proteins are in their most native ensemble of conformational states. The H/D exchange reaction can also be catalysed, by acid, base or metal catalysts such as platinum. For the backbone amide hydrogen atoms of proteins, the minimum exchange rate occurs at approximately pH 2.6, on average. By performing the exchange at neutral pH and then rapidly changing the pH, the exchange rates of the backbone amide hydrogens can be dramatically slowed, or quenched. The pH at which the reaction is quenched depends on the analysis method. For detection by NMR, the pH may be moved to around 4.0–4.5. For detection by mass spectrometry, the pH is dropped to the minimum of the exchange curve, pH 2.6. In the most basic experiment, the reaction is allowed to take place for a set time before it is quenched. The deuteration pattern of a molecule that has undergone H/D exchange can be maintained in aprotic environments.
== Further reading == "New Guidelines Seek to Provide Clarity on Food Expiration Dates". All Things Considered. U.S.: NPR. 17 February 2017. Includes a list of the many terms used in the United States food industry. Anonymous, "Cold Chain Management", 2003, 2006 Anonymous, Protecting Perishable Foods During Transport by Truck Archived 2014-05-16 at the Wayback Machine, USDA Handbook 669, 1995 Kilcast, D., Subramamiam, P., Food and Beverage Stability and Shelf Life, Woodhead Publishing, 2011, ISBN 978-1-84569-701-3 Labuza, T. P., Szybist, L., Open dating of Foods, Food and Nutrition Press, 2001; other edition: Wiley-Blackwell, 2004, ISBN 0-917678-53-2 Man, C. M., Jones. A. A., Shelf-Life Evaluation of Foods, ISBN 0-8342-1782-1 Robertson, G.L., Food Packaging and Shelf Life: A Practical Guide, CRC Press, 2010, ISBN 978-1-4200-7844-2 Steele, R., Understanding and Measuring the Shelf-Life of Food, Woodhead Publishing, 2004, ISBN 1-85573-732-9 Weenen, H., Cadwallader, K., Freshness and Shelf Life of Foods, ACS, 2002, ISBN 0-8412-3801-4
population, comparable to White Americans. In 2018, the opioid crisis continued to disproportionately affect non-Hispanic Whites and Native Americans with the National Institutes of Health (NIH) reporting a rise in opioid morbidity and opioid related fatalities. During 2019–2020, non-Hispanic American Indian/Alaska Native and Black individuals experienced the greatest increases in drug overdose mortality rates. Additionally, American Indian/Alaska Native and Black individuals had the highest opioid overdose rate 2020 and 2021. The percentage of individuals with documentation of prior treatment for substance use disorders was low, especially among Black individuals, at 8.3%. Overall, Hispanics, Native Hawaiians, and Asians experienced the lowest rate of overdose deaths. Though previous statistics show that non-Hispanic White Americans have been affected by the opioid epidemic more than other racial/ethnic groups in the United States, recent statistics show that Black Americans are experiencing a sharper increase in opioid-overdose deaths. The annual percentage change of opioid overdose deaths among Black Americans increased to 26.16 from 2012 to 2018 while White Americans only experienced an 18.96 increase from 2013 to 2016 and even had an annual percentage change decrease to 5.07 from 2016 to 2018. The challenges that non-Hispanic Black Americans face have a disparate impact on the rates of opioid-overdose related deaths when compared to non-Hispanic White Americans who have not dealt with the challenges of structural racism.
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.